1
|
Argan O, Cikrikci K, Uslu H, Gencer N. In vitro effects of thirty-eight cardiac drugs on human serum paraoxonase. Chem Biol Drug Des 2022; 100:80-89. [PMID: 35395139 DOI: 10.1111/cbdd.14054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Revised: 02/26/2022] [Accepted: 04/03/2022] [Indexed: 11/30/2022]
Abstract
In this study, the effects of 38 commonly used cardiac drugs on the human paraoxonase (PON1) were investigated. PON1 was purified from human serum blood by ammonium sulfate precipitation (60%-80%) and hydrophobic interaction chromatography (Sepharose-4B~L-tyrosine~1-napthylamine gel). All of the cardiac drugs inhibited PON1 at the micro molar level. IC50 and Ki values were determined for each drug. The tested drugs displayed potent PON1 inhibitory activity. It was found that the weakest PON1 inhibitors are Irbesartan (Ki : 421.73 µM), Glyceryl Trinitrate (Ki : 351.48 µM), and Apixaban (Ki : 333.27 µM). Bisoprolol hemifumarate (Ki : 269.31 µM) is also other weak PON1 inhibitor. Therefore, these drugs, having weak PON1 inhibitory activity, may be preferred primarily in patients with atheroclerotic heart disease compared to other drugs due to the protective effect of PON1 on atherosclerosis. Conversely, the most potent inhibitors against PON1 were propafenone (Ki : 0.35 µM), Lacidipine (Ki : 0.78 µM), Lidocaine HCl (Ki : 1.78 µM), and Propranolol (Ki : 1.86 µM). Molecular docking was also applied to confirm the activity of some cardiac drugs on PON1.
Collapse
Affiliation(s)
- Onur Argan
- Department of Cardiology, Faculty of Medicine, Balikesir University, Balikesir, Turkey
| | - Kubra Cikrikci
- Department of Chemistry, Science and Art Faculty, Balikesir University, Balikesir, Turkey
| | - Harun Uslu
- Department of Medical Services and Techniques, Vocational School of Health Services, Firat University, Elazig, Turkey
| | - Nahit Gencer
- Department of Chemistry, Science and Art Faculty, Balikesir University, Balikesir, Turkey
| |
Collapse
|
2
|
Multitarget Antioxidant NO-Donor Organic Nitrates: A Novel Approach to Overcome Nitrates Tolerance, an Ex Vivo Study. Antioxidants (Basel) 2022; 11:antiox11010166. [PMID: 35052670 PMCID: PMC8773138 DOI: 10.3390/antiox11010166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Revised: 01/05/2022] [Accepted: 01/14/2022] [Indexed: 12/04/2022] Open
Abstract
Chronic use of glyceryl trinitrate (GTN) is limited by serious side effects, such as tolerance and endothelial dysfunction of coronary and resistance arteries. Although GTN is used as a drug since more than 130 years, the mechanisms of the vasodilatory effects and of tolerance development to organic nitrates are still incompletely elucidated. New synthesized organic nitrates with and without antioxidant properties were characterized for their ex vivo tolerance profile, in order to investigate the oxidative stress hypothesis of nitrate tolerance. The organic nitrates studied showed different vasodilation and tolerance profiles, probably due to the ability or inability of the compounds to interact with the aldehyde dehydrogenase-2 enzyme (ALDH-2) involved in bioactivation. Furthermore, nitrooxy derivatives endowed with antioxidant properties did not determine the onset of tolerance, even if bioactivated by ALDH-2. The results of this study could be further evidence of the involvement of ALDH-2 in the development of nitrate tolerance. Moreover, the behavior of organic nitrates with antioxidant properties supports the hypothesis of the involvement of ROS in inactivating ALDH-2.
Collapse
|
3
|
3-benzazecine-based cyclic allene derivatives as highly potent P-glycoprotein inhibitors overcoming doxorubicin multidrug resistance. Future Med Chem 2019; 11:2095-2106. [DOI: 10.4155/fmc-2019-0037] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Aim: Enamino 3-benzazecine compounds, incorporating the C6-C8 allene system, were synthesized and evaluated in vitro as inhibitors of P-glycoprotein (P-gp) and/or multidrug resistance-associated protein 1 (MRP1), two efflux pumps mainly connected with multidrug resistance (MDR) in cancer cells. Results & methodology: Most of the synthesized compounds were selective P-gp inhibitors in Calcein-AM uptake assay. Structure–activity relationships (SARs) pointed out that CO2Me derivatives are more potent than acetyl derivatives, and 10,11-dimethoxy compounds are five to tenfold more potent inhibitors than the respective unsubstituted compounds, and that the P-gp inhibition potency is mainly related to volume parameters. Conclusion: Nanomolar P-gp inhibitors, such as 23 (IC50 = 4.2 nM), restored the antiproliferative activity of doxorubicin in multidrug-resistant cells. The observed activities showed that 3-benzazecine-based compounds may be promising MDR reversers.
Collapse
|
4
|
Purgatorio R, de Candia M, Catto M, Carrieri A, Pisani L, De Palma A, Toma M, Ivanova OA, Voskressensky LG, Altomare CD. Investigating 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole as scaffold of butyrylcholinesterase-selective inhibitors with additional neuroprotective activities for Alzheimer's disease. Eur J Med Chem 2019; 177:414-424. [PMID: 31158754 DOI: 10.1016/j.ejmech.2019.05.062] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2019] [Revised: 05/13/2019] [Accepted: 05/23/2019] [Indexed: 12/19/2022]
Abstract
Due to the role of butyrylcholinesterase (BChE) in acetylcholine hydrolysis in the late stages of the Alzheimer's disease (AD), inhibitors of butyrylcholinesterase (BChE) have been recently envisaged, besides acetylcholinesterase (AChE) inhibitors, as candidates for treating mild-to-moderate AD. Herein, synthesis and AChE/BChE inhibition activity of some twenty derivatives of 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole (HHAI) is reported. Most of the newly synthesized HHAI derivatives achieved the inhibition of both ChE isoforms with IC50s in the micromolar range, with a structure-dependent selectivity toward BChE. Apparently, molecular volume and lipophilicity do increase selectivity toward BChE, and indeed the N2-(4-phenylbutyl) HHAI derivative 15d, which behaves as a mixed-type inhibitor, resulted the most potent (IC50 0.17 μM) and selective (>100-fold) inhibitor toward either horse serum and human BChE. Moreover, 15d inhibited in vitro self-induced aggregation of neurotoxic amyloid-β (Aβ) peptide and displayed neuroprotective effects in neuroblastoma SH-SY5Y cell line, significantly recovering (P < 0.001) cell viability when impaired by Aβ1-42 and hydrogen peroxide insults. Overall, this study highlighted HHAI as useful and versatile scaffold for developing new small molecules targeting some enzymes and biochemical pathways involved in the pathogenesis of AD.
Collapse
Affiliation(s)
- Rosa Purgatorio
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Modesto de Candia
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy.
| | - Marco Catto
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Antonio Carrieri
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Leonardo Pisani
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Annalisa De Palma
- Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Maddalena Toma
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Olga A Ivanova
- Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1-3, Moscow, 119991, Russian Federation
| | - Leonid G Voskressensky
- Organic Chemistry Department, RUDN University, Miklukho-Maklai St, 6, Moscow, 117198, Russian Federation
| | - Cosimo D Altomare
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| |
Collapse
|
5
|
Magliocca S, De Caro C, Lazzarato L, Russo R, Rolando B, Chegaev K, Marini E, Nieddu M, Burrai L, Boatto G, Cristiano C, Marabello D, Gazzano E, Riganti C, Sodano F, Rimoli MG. Aceclofenac–Galactose Conjugate: Design, Synthesis, Characterization, and Pharmacological and Toxicological Evaluations. Mol Pharm 2018; 15:3101-3110. [DOI: 10.1021/acs.molpharmaceut.8b00195] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Salvatore Magliocca
- Department of Pharmacy, “Federico II” University of Naples, 80131 Naples, Italy
| | - Carmen De Caro
- Department of Pharmacy, “Federico II” University of Naples, 80131 Naples, Italy
- Department of Science of Health, School of Medicine and Surgery, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, Italy
| | | | - Roberto Russo
- Department of Pharmacy, “Federico II” University of Naples, 80131 Naples, Italy
| | | | | | | | - Maria Nieddu
- Department of Chemistry and Pharmacy, University of Sassari, 07100, Sassari, Italy
| | - Lucia Burrai
- Department of Chemistry and Pharmacy, University of Sassari, 07100, Sassari, Italy
| | - Gianpiero Boatto
- Department of Chemistry and Pharmacy, University of Sassari, 07100, Sassari, Italy
| | - Claudia Cristiano
- Department of Pharmacy, “Federico II” University of Naples, 80131 Naples, Italy
| | - Domenica Marabello
- Interdepartmental Center
for Crystallography (CrisDi), 10125 Torino, Italy
| | - Elena Gazzano
- Department of Oncology, University of Torino, 10126 Torino, Italy
| | - Chiara Riganti
- Department of Oncology, University of Torino, 10126 Torino, Italy
| | | | - Maria Grazia Rimoli
- Department of Pharmacy, “Federico II” University of Naples, 80131 Naples, Italy
| |
Collapse
|
6
|
Cassano T, Lopalco A, de Candia M, Laquintana V, Lopedota A, Cutrignelli A, Perrone M, Iacobazzi RM, Bedse G, Franco M, Denora N, Altomare CD. Oxazepam-Dopamine Conjugates Increase Dopamine Delivery into Striatum of Intact Rats. Mol Pharm 2017; 14:3178-3187. [PMID: 28780872 DOI: 10.1021/acs.molpharmaceut.7b00405] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The neurotransmitter dopamine (DA) was covalently linked to oxazepam (OXA), a well-known positive allosteric modulator of γ-aminobutyric acid type-A (GABAA) receptor, through a carbamate linkage (4) or a succinic spacer (6). These conjugates were synthesized with the aim of improving the delivery of DA into the brain and enhancing GABAergic transmission, which may be useful for the long-term treatment of Parkinson disease (PD). Structure-based permeability properties, in vitro stability, and blood-brain barrier (BBB) permeability studies led to identify the OXA-DA carbamate conjugate 4a as the compound better combining sufficient stability and ability to cross BBB. Finally, in vivo microdialysis experiments in freely moving rats demonstrated that 4a (20 mg/kg, i.p.) significantly increases extracellular DA levels into striatum, with a peak (more than 15-fold increase over the baseline) at about 80 min after a single administration. The stability and delivery data proved that 4a may be a promising candidate for further pharmacological studies in animal models of PD.
Collapse
Affiliation(s)
- Tommaso Cassano
- Department of Clinical and Experimental Medicine, University of Foggia , Foggia 71100, Italy
| | - Antonio Lopalco
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro , Bari 70125, Italy
| | - Modesto de Candia
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro , Bari 70125, Italy
| | - Valentino Laquintana
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro , Bari 70125, Italy
| | - Angela Lopedota
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro , Bari 70125, Italy
| | - Annalisa Cutrignelli
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro , Bari 70125, Italy
| | - Mara Perrone
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro , Bari 70125, Italy
| | - Rosa M Iacobazzi
- Istituto tumori IRCCS "Giovanni Paolo II" , Flacco, St. 65, 70124 Bari, Italy
| | - Gaurav Bedse
- Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome , 00185 Rome, Italy.,Department of Psychiatry, Vanderbilt University Medical Center , Nashville, Tennessee 37232, United States
| | - Massimo Franco
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro , Bari 70125, Italy
| | - Nunzio Denora
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro , Bari 70125, Italy
| | - Cosimo D Altomare
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro , Bari 70125, Italy
| |
Collapse
|
7
|
Overview of Antagonists Used for Determining the Mechanisms of Action Employed by Potential Vasodilators with Their Suggested Signaling Pathways. Molecules 2016; 21:495. [PMID: 27092479 PMCID: PMC6274436 DOI: 10.3390/molecules21040495] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Revised: 03/23/2016] [Accepted: 03/28/2016] [Indexed: 01/04/2023] Open
Abstract
This paper is a review on the types of antagonists and the signaling mechanism pathways that have been used to determine the mechanisms of action employed for vasodilation by test compounds. Thus, we exhaustively reviewed and analyzed reports related to this topic published in PubMed between the years of 2010 till 2015. The aim of this paperis to suggest the most appropriate type of antagonists that correspond to receptors that would be involved during the mechanistic studies, as well as the latest signaling pathways trends that are being studied in order to determine the route(s) that atest compound employs for inducing vasodilation. The methods to perform the mechanism studies were included. Fundamentally, the affinity, specificity and selectivity of the antagonists to their receptors or enzymes were clearly elaborated as well as the solubility and reversibility. All the signaling pathways on the mechanisms of action involved in the vascular tone regulation have been well described in previous review articles. However, the most appropriate antagonists that should be utilized have never been suggested and elaborated before, hence the reason for this review.
Collapse
|